S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NYSE:AZN - AstraZeneca Stock Price, Forecast & News

$47.85
-1.48 (-3.00 %)
(As of 02/17/2020 04:00 PM ET)
Today's Range
$47.40
Now: $47.85
$48.22
50-Day Range
$48.51
MA: $49.88
$51.33
52-Week Range
$36.83
Now: $47.85
$51.55
Volume6.67 million shs
Average Volume2.72 million shs
Market Capitalization$125.55 billion
P/E Ratio90.28
Dividend Yield1.84%
Beta0.48
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-3749-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.38 billion
Cash Flow$3.21 per share
Book Value$5.54 per share

Profitability

Net Income$1.34 billion

Miscellaneous

Employees64,400
Outstanding Shares2,623,760,000
Market Cap$125.55 billion
Next Earnings Date4/24/2020 (Estimated)
OptionableOptionable

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.


AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) issued its quarterly earnings data on Friday, February, 14th. The company reported $0.45 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.53 by $0.08. The firm had revenue of $6.66 billion for the quarter, compared to the consensus estimate of $6.75 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 5.38%. AstraZeneca's revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for AstraZeneca.

What price target have analysts set for AZN?

12 brokers have issued 1-year price objectives for AstraZeneca's stock. Their forecasts range from $40.73 to $57.00. On average, they anticipate AstraZeneca's stock price to reach $50.68 in the next year. This suggests a possible upside of 5.9% from the stock's current price. View Analyst Price Targets for AstraZeneca.

What is the consensus analysts' recommendation for AstraZeneca?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

News articles about AZN stock have trended extremely negative on Monday, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for AstraZeneca.

Who are some of AstraZeneca's key competitors?

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AT&T (T), AbbVie (ABBV), Bank of America (BAC), Cisco Systems (CSCO), Merck & Co., Inc. (MRK), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC) and Bristol-Myers Squibb (BMY).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Gen. Counsel

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.02%), Jennison Associates LLC (1.40%), Bank of America Corp DE (0.35%), GQG Partners LLC (0.27%), Franklin Resources Inc. (0.21%) and Bank of Montreal Can (0.09%). View Institutional Ownership Trends for AstraZeneca.

Which major investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bank of America Corp DE, Marshall Wace LLP, Bank of Montreal Can, Schafer Cullen Capital Management Inc, Russell Investments Group Ltd., Charles Schwab Investment Management Inc. and Becker Capital Management Inc.. View Insider Buying and Selling for AstraZeneca.

Which major investors are buying AstraZeneca stock?

AZN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, GQG Partners LLC, Renaissance Technologies LLC, Jennison Associates LLC, Galibier Capital Management Ltd., Ariose Capital Management Ltd, Sectoral Asset Management Inc and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $47.85.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $125.55 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

What is AstraZeneca's official website?

The official website for AstraZeneca is http://www.astrazeneca.com/.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (NYSE AZN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  737 (Vote Outperform)
Underperform Votes:  1,202 (Vote Underperform)
Total Votes:  1,939
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel